TRCT
IART icon

Tower Research Capital (TRC)’s Integra LifeSciences IART Stock Holding History

Tower Research Capital (TRC)’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.6K Buy
6,005
+2,833
+89% +$31.1K ﹤0.01% 2635
2025
Q4 		$39.4K Sell
3,172
-2,112
-40% -$28.1K ﹤0.01% 2610
2025
Q3 		$75.7K Sell
5,284
-2,674
-34% -$36.6K ﹤0.01% 2217
2025
Q2 		$97.6K Buy
7,958
+6,814
+596% +$98.9K ﹤0.01% 2398
2025
Q1 		$25.2K Sell
1,144
-17,703
-94% -$416K ﹤0.01% 2764
2024
Q4 		$427K Buy
18,847
+14,985
+388% +$327K 0.01% 1176
2024
Q3 		$70.2K Sell
3,862
-10,357
-73% -$240K ﹤0.01% 2517
2024
Q2 		$414K Buy
14,219
+10,389
+271% +$308K 0.01% 1492
2024
Q1 		$136K Sell
3,830
-5,108
-57% -$204K ﹤0.01% 1655
2023
Q4 		$389K Buy
8,938
+3,733
+72% +$147K ﹤0.01% 1575
2023
Q3 		$199K Sell
5,205
-2,088
-29% -$87.8K 0.01% 1439
2023
Q2 		$300K Sell
7,293
-5,310
-42% -$256K 0.01% 1291
2023
Q1 		$723K Buy
12,603
+11,185
+789% +$630K 0.02% 619
2022
Q4 		$80K Sell
1,418
-928
-40% -$47.2K ﹤0.01% 2004
2022
Q3 		$99K Sell
2,346
-1,929
-45% -$98.8K ﹤0.01% 2566
2022
Q2 		$231K Sell
4,275
-7,350
-63% -$441K 0.01% 1659
2022
Q1 		$747K Buy
11,625
+2,598
+29% +$171K 0.01% 921
2021
Q4 		$605K Buy
9,027
+1,727
+24% +$117K 0.01% 987
2021
Q3 		$500K Buy
7,300
+1,498
+26% +$106K 0.01% 990
2021
Q2 		$396K Buy
5,802
+2,145
+59% +$152K 0.01% 1370
2021
Q1 		$253K Sell
3,657
-13,721
-79% -$930K ﹤0.01% 1802
2020
Q4 		$1.13M Sell
17,378
-2,639
-13% -$142K 0.03% 452
2020
Q3 		$945K Sell
20,017
-723
-3% -$34.4K 0.01% 1059
2020
Q2 		$974K Buy
20,740
+20,189
+3,664% +$992K 0.04% 540
2020
Q1 		$25K Sell
551
-5,027
-90% -$264K ﹤0.01% 1607
2019
Q4 		$325K Buy
5,578
+5,023
+905% +$299K 0.03% 412
2019
Q3 		$33K Sell
555
-259
-32% -$15.4K ﹤0.01% 2098
2019
Q2 		$46K Sell
814
-5,486
-87% -$283K ﹤0.01% 1617
2019
Q1 		$351K Buy
+6,300
New +$321K 0.02% 832
2018
Q4 		– Sell
-6,904
Closed -$455K – 4049
2018
Q3 		$455K Buy
6,904
+1,156
+20% +$71.8K 0.03% 527
2018
Q2 		$370K Buy
5,748
+5,486
+2,094% +$340K 0.02% 776
2018
Q1 		$14K Buy
+262
New +$13.7K ﹤0.01% 2332
2017
Q4 		– Sell
-6,538
Closed -$330K – 3733
2017
Q3 		$330K Buy
+6,538
New +$336K 0.03% 438
2017
Q1 		– Sell
-1,550
Closed -$66K – 3434
2016
Q4 		$66K Buy
+1,550
New +$63K 0.01% 1226
2016
Q3 		– Sell
-4,908
Closed -$196K – 3983
2016
Q2 		$196K Buy
4,908
+4,308
+718% +$155K 0.02% 673
2016
Q1 		$20K Buy
+600
New +$18.7K ﹤0.01% 1345
2015
Q3 		– Sell
-859
Closed -$24K – 4336
2015
Q2 		$24K Sell
859
-1,837
-68% -$49K ﹤0.01% 1938
2015
Q1 		$68K Buy
+2,696
New +$63.7K 0.01% 1219
2014
Q4 		– Sell
-2,537
Closed -$51.4K – 4303
2014
Q3 		$51K Sell
2,537
-423
-14% -$8.42K 0.01% 1514
2014
Q2 		$57K Buy
2,960
+2,693
+1,009% +$50.2K 0.01% 1208
2014
Q1 		$5K Buy
267
+130
+95% +$2.51K ﹤0.01% 3257
2013
Q4 		$3K Buy
+137
New +$2.51K ﹤0.01% 3842

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Tower Research Capital (TRC)'s IART Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Integra LifeSciences (IART) stake by 89% in Q1 2026, buying an estimated $31.1K and bringing the position to 6,005 shares worth $56.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2635.

Tower Research Capital (TRC) first reported a position in IART in Q4 2013 and has held it in 42 quarters since. The position peaked at $1.13M in Q4 2020. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Tower Research Capital (TRC) held 6,005 shares of Integra LifeSciences worth $56.6K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,833 Integra LifeSciences shares in Q1 2026, an estimated $31.1K.
  • Integra LifeSciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2635 holding.
  • Tower Research Capital (TRC) first reported a position in Integra LifeSciences in Q4 2013 and has held it in 42 quarters since.
  • Tower Research Capital (TRC)'s Integra LifeSciences position peaked at $1.13M in Q4 2020.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.